The Asp298 allele of endothelial nitric oxide synthase is a risk factor for myocardial infarction among patients with type 2 diabetes mellitus

[1]  L. Råstam,et al.  The Skaraborg hypertension project. II. Feasibility of a medical care program for hypertension. , 2009, Acta medica Scandinavica.

[2]  L. Råstam,et al.  The Skaraborg hypertension project. III. Influence on blood pressure of a medical care program for hypertension. , 2009, Acta medica Scandinavica.

[3]  R. Testa,et al.  Platelet nitric oxide production and IR: relation with obesity and hypertriglyceridemia. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[4]  P. Ridker,et al.  Renin–angiotensin and endothelial nitric oxide synthase gene polymorphisms are not associated with the risk of incident type 2 diabetes mellitus: a prospective cohort study , 2008, Journal of internal medicine.

[5]  Amit A. Doshi,et al.  Endothelial nitric oxide synthase gene: prospects for treatment of heart disease. , 2007, Pharmacogenomics.

[6]  J. Tanus-Santos,et al.  Modulation of nitric oxide formation by endothelial nitric oxide synthase gene haplotypes. , 2007, Free radical biology & medicine.

[7]  J. Manson,et al.  Circulating Levels of Endothelial Adhesion Molecules and Risk of Diabetes in an Ethnically Diverse Cohort of Women , 2007, Diabetes.

[8]  U. Förstermann.  Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal , 2006, Biological chemistry.

[9]  L. Råstam,et al.  Residual risk for acute stroke in patients with type 2 diabetes and hypertension in primary care: Skaraborg Hypertension and Diabetes Project , 2006, Diabetes, obesity & metabolism.

[10]  G. Schuler,et al.  Endothelial Protection, AT1 Blockade and Cholesterol-Dependent Oxidative Stress: The EPAS Trial , 2006, Circulation.

[11]  F. Leighton,et al.  A central role of eNOS in the protective effect of wine against metabolic syndrome , 2006, Cell biochemistry and function.

[12]  S. Moncada,et al.  Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis. , 2005, European heart journal.

[13]  L. Råstam,et al.  Female advantage in AMI mortality is reversed in patients with type 2 diabetes in the Skaraborg Project. , 2005, Diabetes care.

[14]  U. Ekelund,et al.  Variation in the eNOS gene modifies the association between total energy expenditure and glucose intolerance. , 2005, Diabetes.

[15]  M. Uhlén,et al.  Pyrosequencing analysis of thrombosis-associated risk markers. , 2005, Clinical chemistry.

[16]  G A Colditz,et al.  Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. , 2004, Preventive medicine.

[17]  J. Manson,et al.  Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. , 2004, JAMA.

[18]  S. Humphries,et al.  Endothelial Nitric Oxide Synthase Genotype and Ischemic Heart Disease: Meta-Analysis of 26 Studies Involving 23028 Subjects , 2004, Circulation.

[19]  P. Marsden,et al.  Endothelial Nitric Oxide Synthase: A New Paradigm for Gene Regulation in the Injured Blood Vessel , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[20]  J. Beckman,et al.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I , 2013, European heart journal.

[21]  Xiang-An Li,et al.  HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. , 2003, The Journal of clinical investigation.

[22]  L. Bernardinelli,et al.  Endothelial nitric oxide synthase polymorphisms are associated with type 2 diabetes and the insulin resistance syndrome. , 2003, Diabetes.

[23]  P. Doevendans,et al.  The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide , 2002, Journal of hypertension.

[24]  G. Kojda,et al.  Vasoprotection by nitric oxide: mechanisms and therapeutic potential. , 2002, Cardiovascular research.

[25]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[26]  P. Libby.  Managing the risk of atherosclerosis: the role of high-density lipoprotein. , 2001, American Journal of Cardiology.

[27]  Richard G. W. Anderson,et al.  High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase , 2001, Nature Medicine.

[28]  K. Matthews,et al.  Changes in Cardiovascular Risk Factors During the Perimenopause and Postmenopause and Carotid Artery Atherosclerosis in Healthy Women , 2001, Stroke.

[29]  N. Taniguchi,et al.  Estrogen Induces the Akt-dependent Activation of Endothelial Nitric-oxide Synthase in Vascular Endothelial Cells* , 2001, The Journal of Biological Chemistry.

[30]  M. Mendelsohn.  Mechanisms of estrogen action in the cardiovascular system , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[31]  J. Ranstam,et al.  Associations between smoking and β‐cell function in a non‐hypertensive and non‐diabetic populationSkaraborg Hypertension and Diabetes Project , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[32]  L. Råstam,et al.  Comparison of different procedures to identify probable cases of myocardial infarction and stroke in two Swedish prospective cohort studies using local and national routine registers , 2000, European Journal of Epidemiology.

[33]  J. Ranstam,et al.  Differences in treatment and metabolic abnormalities between normo- and hypertensive patients with type 2 diabetes: the Skaraborg Hypertension and Diabetes Project. , 1999, Diabetes, obesity & metabolism.

[34]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[35]  H Yasue,et al.  Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. , 1998, Journal of the American College of Cardiology.

[36]  J. Ranstam,et al.  Risk factor clustering in patients with hypertension and non‐insulin‐dependent diabetes mellitus. The Skaraborg Hypertension Project , 1998, Journal of internal medicine.

[37]  L. Ghiadoni,et al.  Menopause is associated with endothelial dysfunction in women. , 1996, Hypertension.

[38]  J. Ranstam,et al.  Validity of register data on acute myocardial infarction and acute stroke , 1993, Scandinavian journal of social medicine.

[39]  S. Moncada,et al.  ENDOGENOUS NITRIC OXIDE INHIBITS HUMAN PLATELET ADHESION TO VASCULAR ENDOTHELIUM , 1987, The Lancet.

[40]  C. Mathew,et al.  Blot hybridisation analysis of genomic DNA. , 1984, Journal of medical genetics.

[41]  A. Gardemann,et al.  The T allele of the missense Glu(298)Asp endothelial nitric oxide synthase gene polymorphism is associated with coronary heart disease in younger individuals with high atherosclerotic risk profile. , 2002, Atherosclerosis.

[42]  嶋崎 幸生.  Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction , 1999 .

[43]  G. Colditz,et al.  Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence☆☆☆ , 1991 .

[44]  C. K. Smith,et al.  Treatment of mild hypertension , 1990 .